Cargando…
Case Report: Off Label Utilization of Topiramate and Metformin in Patients With BMI ≥50 kg/m(2) Prior to Bariatric Surgery
FDA approved anti-obesity medications may not be cost effective for patients struggling with pre-operative weight loss prior to bariatric surgery. Metformin, a biguanide, and Topiramate, a carbonic anhydrase inhibitor, both cost effective medications, have demonstrated weight loss when used for the...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947603/ https://www.ncbi.nlm.nih.gov/pubmed/33716960 http://dx.doi.org/10.3389/fendo.2021.588016 |
_version_ | 1783663261144580096 |
---|---|
author | Sari, Cetin Seip, Richard L. Umashanker, Devika |
author_facet | Sari, Cetin Seip, Richard L. Umashanker, Devika |
author_sort | Sari, Cetin |
collection | PubMed |
description | FDA approved anti-obesity medications may not be cost effective for patients struggling with pre-operative weight loss prior to bariatric surgery. Metformin, a biguanide, and Topiramate, a carbonic anhydrase inhibitor, both cost effective medications, have demonstrated weight loss when used for the treatment of type 2 diabetes or seizures, respectively. The aim of the three cases is to demonstrate the clinical utility of topiramate and metformin for preoperative weight loss in patients with a body mass index (BMI) ≥ 50 kg/m(2) prior to bariatric surgery who are unable to follow the bariatric nutritional prescription due to a dysregulated appetite system Each patient was prescribed metformin and/or topiramate in an off-label manner in conjunction with lifestyle modifications and achieved >8% total body weight loss during the preoperative period. |
format | Online Article Text |
id | pubmed-7947603 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79476032021-03-12 Case Report: Off Label Utilization of Topiramate and Metformin in Patients With BMI ≥50 kg/m(2) Prior to Bariatric Surgery Sari, Cetin Seip, Richard L. Umashanker, Devika Front Endocrinol (Lausanne) Endocrinology FDA approved anti-obesity medications may not be cost effective for patients struggling with pre-operative weight loss prior to bariatric surgery. Metformin, a biguanide, and Topiramate, a carbonic anhydrase inhibitor, both cost effective medications, have demonstrated weight loss when used for the treatment of type 2 diabetes or seizures, respectively. The aim of the three cases is to demonstrate the clinical utility of topiramate and metformin for preoperative weight loss in patients with a body mass index (BMI) ≥ 50 kg/m(2) prior to bariatric surgery who are unable to follow the bariatric nutritional prescription due to a dysregulated appetite system Each patient was prescribed metformin and/or topiramate in an off-label manner in conjunction with lifestyle modifications and achieved >8% total body weight loss during the preoperative period. Frontiers Media S.A. 2021-02-25 /pmc/articles/PMC7947603/ /pubmed/33716960 http://dx.doi.org/10.3389/fendo.2021.588016 Text en Copyright © 2021 Sari, Seip and Umashanker https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Sari, Cetin Seip, Richard L. Umashanker, Devika Case Report: Off Label Utilization of Topiramate and Metformin in Patients With BMI ≥50 kg/m(2) Prior to Bariatric Surgery |
title | Case Report: Off Label Utilization of Topiramate and Metformin in Patients With BMI ≥50 kg/m(2) Prior to Bariatric Surgery |
title_full | Case Report: Off Label Utilization of Topiramate and Metformin in Patients With BMI ≥50 kg/m(2) Prior to Bariatric Surgery |
title_fullStr | Case Report: Off Label Utilization of Topiramate and Metformin in Patients With BMI ≥50 kg/m(2) Prior to Bariatric Surgery |
title_full_unstemmed | Case Report: Off Label Utilization of Topiramate and Metformin in Patients With BMI ≥50 kg/m(2) Prior to Bariatric Surgery |
title_short | Case Report: Off Label Utilization of Topiramate and Metformin in Patients With BMI ≥50 kg/m(2) Prior to Bariatric Surgery |
title_sort | case report: off label utilization of topiramate and metformin in patients with bmi ≥50 kg/m(2) prior to bariatric surgery |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947603/ https://www.ncbi.nlm.nih.gov/pubmed/33716960 http://dx.doi.org/10.3389/fendo.2021.588016 |
work_keys_str_mv | AT saricetin casereportofflabelutilizationoftopiramateandmetformininpatientswithbmi50kgm2priortobariatricsurgery AT seiprichardl casereportofflabelutilizationoftopiramateandmetformininpatientswithbmi50kgm2priortobariatricsurgery AT umashankerdevika casereportofflabelutilizationoftopiramateandmetformininpatientswithbmi50kgm2priortobariatricsurgery |